Title:
レンバチニブ及びＰＤ－１アンタゴニストを含む組み合わせ療法のためのバイオマーカー
Document Type and Number:
Japanese Patent JP7401460
Kind Code:
B2
Abstract:
Biomarkers are provided that are predictive of a subject's responsiveness to a combination therapy comprising lenvatinib compound and a PD-1 antagonist. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing cancer.
More Like This:
Inventors:
Yasuhiro Funabashi
Kotaro Kodama
Ryo Oiriki
Yukinori Minoshima
Kotaro Kodama
Ryo Oiriki
Yukinori Minoshima
Application Number:
JP2020560740A
Publication Date:
December 19, 2023
Filing Date:
May 13, 2019
Export Citation:
Assignee:
Merck Sharp & Dome LLC
Eisai R&D Management Co., Ltd.
Eisai R&D Management Co., Ltd.
International Classes:
G01N33/53; A61K31/47; A61K39/395; A61K45/00; A61P35/00; A61P43/00
Domestic Patent References:
| JP2014521308A |
Foreign References:
| WO2016141218A1 |
Other References:
Yu Kato et al,Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors,Molecular Cancer Therapeutics,2015年,14(12_Supplement_2),A92
M.Taylor et al,A phase 1b trial of lenvatinib(LEN) plus pembrolizumab(PEM) in patients with selected solid cancers,Annals of Oncology,2016年,26
Makoto Tahara et al,Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid,European Journal of Cancer,2017年,75,213-221
M.Taylor et al,A phase 1b trial of lenvatinib(LEN) plus pembrolizumab(PEM) in patients with selected solid cancers,Annals of Oncology,2016年,26
Makoto Tahara et al,Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid,European Journal of Cancer,2017年,75,213-221
Attorney, Agent or Firm:
Yoshiki Hasegawa
Yoshinori Shimizu
Katsusuke Kimoto
Yoshinori Shimizu
Katsusuke Kimoto